High incidence of co-existing factors significantly modifying the phenotype in patients with Fabry disease.
Adolescent
Adult
Biomarkers
/ metabolism
Case-Control Studies
Child
Child, Preschool
Fabry Disease
/ epidemiology
Female
Follow-Up Studies
Genetic Variation
Heterozygote
Humans
Male
Middle Aged
Pedigree
Phenotype
Prognosis
Risk Factors
Turkey
/ epidemiology
Young Adult
alpha-Galactosidase
/ genetics
Fabry disease
Family screening
Phenotype modifiers
X-inactivation
Journal
Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761
Informations de publication
Date de publication:
01 Mar 2019
01 Mar 2019
Historique:
received:
30
07
2018
accepted:
16
11
2018
pubmed:
24
11
2018
medline:
19
1
2019
entrez:
24
11
2018
Statut:
ppublish
Résumé
Fabry disease results from deficiency of the lysosomal enzyme alpha-galactosidase A. The families of 11 index cases were screened by enzyme and molecular assays. Further clinical and laboratory investigations were carried out in all cases. Including 33 new patients, a total of 28 females (Age 25,82 ± 12,1 Range 8-46) and 16 males (Age 24,56 ± 15,04 Range 2-48) were investigated. Ten different disease-causing variants were found two of them being novel. One patient had co-existing familial mediteranian fever, one had celiac disease and three had rheumatological disorders. Lipoprotein (a) levels were elevated in 17,6%, homocysteine in 22,2%, total and low density cholesterol in 12% and antithrombin 3 levels were elevated in 13,3%. One patient was found to be heterozygous for prothrombin p.G20210A disease-causing variant (5,8%) and two for factor V Leiden disease-causing variant (11,7%). Anticardiolipin IgM antibody was found to be positive in 11,7%. The patients with abnormal cranial imaging were also noticed to have additional risk factors for thrombosis. This study provides the largest data about Fabry patients from Turkey and implies that co-existing risk factors unrelated to Fabry Disease have significant association with the presence of clinical symptoms in females and might cause an early and severe clinical course in males.
Identifiants
pubmed: 30468909
pii: S0378-1119(18)31198-3
doi: 10.1016/j.gene.2018.11.054
pii:
doi:
Substances chimiques
Biomarkers
0
alpha-Galactosidase
EC 3.2.1.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280-288Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.